| Overview |
| bsm-51379M |
| MB21D1 (7E3) Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This MB21D1 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 1-185 amino acids from human MB21D1. |
| Monoclonal |
| 7.00E+03 |
| IgG1 |
| 0.5ug/ul |
| Purified by Protein G. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 115004 |
| Q8N884 |
| cGAS; h-cGAS; C6orf150; Cyclic GMP-AMP synthase; cGAMP synthase; 2'3'-cGAMP synthase; Mab-21 domain-containing protein 1; MB21D1 |
| Nucleotidyltransferase that catalyzes the formation of cyclic GMP-AMP (cGAMP) from ATP and GTP. Catalysis involves both the formation of a 2',5' phosphodiester linkage at the GpA step and the formation of a 3',5' phosphodiester linkage at the ApG step, producing c[G(2',5')pA(3',5')p]. Has antiviral activity by acting as a key cytosolic DNA sensor, the presence of double-stranded DNA (dsDNA) in the cytoplasm being a danger signal that triggers the immune responses. Binds cytosolic DNA directly, leading to activation and synthesis of cGAMP, a second messenger that binds to and activates TMEM173/STING, thereby triggering type-I interferon production. cGAMP can be transferred between cells by virtue of packaging within viral particles contributing to IFN-induction in newly infected cells in a cGAS-independent but TMEM173/STING-dependent manner (PubMed:26229115). |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz